Sami Labs Appoints Neeraja Shetty as its Chief Executive Officer

Share on facebook
Share on twitter
Share on linkedin
Bengaluru, March 02, 2020: Sami-Sabinsa Group, a pioneer & global leader in health science, today announced the appointment of Ms. Neeraja Shetty as the Chief Executive Officer of Sami Labs (a part of Sami-Sabinsa Group).

Press Release
Sami Labs Appoints Neeraja Shetty as its Chief Executive Officer
Bengaluru, March 02, 2020: Sami-Sabinsa Group, a pioneer & global leader in health science, today announced the appointment of Ms. Neeraja Shetty as the Chief Executive Officer of Sami Labs (a part of Sami-Sabinsa Group). As the CEO, Neeraja will oversee and drive key functions of strategy, operations, supply chain, finance and new projects to help achieve the ambitious growth plans of the company. During her previous assignments with Sami Labs, Neeraja held the positions of CEO – Formulations between 2002 to 2008 and was the Director & President – Strategy & Business Development from 2011 to 2017.
Speaking about her new role, Neeraja said, “It is an exciting time to join Sami Labs as the Group has chalked out an aggressive growth and expansion plan. I look forward to working with teams across the board to drive forward the vision of the organization which is to further consolidate its leadership position in the nutraceuticals and cosmeceuticals space”.
Neeraja possesses over two and half decades of rich experience in the life sciences space and has held various senior management and leadership roles of increasing responsibility, both in India and abroad with a focus on strategy, business development and sales.
She started her career with Biocon and later relocated to Singapore to join Corporate Physicians International as a Country Manager for Singapore, India and Malaysia.
Neeraja also began a life science start up entrepreneurial venture – Igenerix Pharma Pvt Ltd and ran it successfully.
About Sami-Sabinsa Group:
Sami-Sabinsa Group, a pioneer and global leader in health science, is a leading producer of nutraceuticals, cosmeceuticals, standardized herbal extracts, fine chemicals, specialty chemicals, and probiotics. Founded in 1988 by Dr. Muhammed Majeed, an internationally acclaimed scientist turned entrepreneur in the field of Alternative Medicine, the Group has independent research divisions including Natural Drugs, Phytochemistry, Synthetic Chemistry, Tissue Culture, Biotechnology, Analytical R&D, Biological Research, Microbiology, and Formulations R&D, all of which coordinate in a synergistic work model to create products

meeting international standards. Sami-Sabinsa, under the visionary leadership of Dr. Majeed, has pioneered the contract farming model deploying close to 40,000 acres of land, demonstrating its commitment to sustainable development. A team of 120 research scientists works tirelessly to discover and develop standardized natural extracts that render alternative therapy to emerging nutritional and health requirements across the globe. The Group has a sizeable patent portfolio comprising over 240 granted patents and 290+ pending patent applications worldwide. Sami-Sabinsa manufactures its products per global standards at its seven state-of-the-art manufacturing facilities across the globe, which are all accredited with ISO22000:2005, FSSAI. For more information visit samilabs.com.

For media inquiries, please contact:
Meghna / PRHUB: +91-62994-04815/meghna@prhub.com